Changes of serum P62 and Beclin 1 in patients with pulmonary embolism during treatment and their predictive value for efficacy

In patients with APE, serum P62 decreased, but serum Beclin 1 increased. So, both indictors can be applied for diagnosis, efficacy prediction and recurrence prediction of APE.

In this retrospective study, 84 patients diagnosed as APE in Ningbo First Hospital from January 2020 to January 2022 were enrolled and assigned to a patient group, and 40 healthy individuals who underwent physical examination in Ningbo First Hospital during the same time period were assigned to a control group. Serum P62 and Beclin 1 expressions were compared between the two groups, and receiver operating characteristic (ROC) curves were drawn to analyze the diagnostic value of serum P62 and Beclin 1. The changes of serum P62 and Beclin 1 before and after treatment were evaluated. The correlations of P62 and Beclin 1 levels with the efficacy in patients were analyzed, and corresponding ROC curves were drawn. Additionally, the expressions of serum P62 and Beclin 1 in patients with different disease degrees were determined, and their expressions in relapsed patients were compared before treatment.

This study was designed to analyze the changes of serum P62 and Beclin 1 in patients with acute pulmonary embolism (APE) during treatment and their predictive value for efficacy.

The patient group showed significantly lower level of serum P62 but higher level of Beclin 1 than the control group (P<0.05). The areas of under the curves (AUCs) of P62 and Beclin 1 in diagnosing APE were 0.888 and 0.795 respectively. After treatment, patients showed significantly increased P62 expression (P<0.05) and significantly decreased Beclin 1 expression (P<0.01). The P62 expression increased with the relief of patient's disease, with a positive correlation with the patient's disease condition, while the Beclin 1 expression decreased with the relief of patient's disease, with a negative correlation with the patient's disease condition (P<0.05). In addition, the improved group showed significantly higher serum P62 expression (P<0.05) and significantly lower serum Beclin 1 expression than the non-improved group (P<0.05), and the AUCs of P62 and Beclin 1 in predicting the efficacy in patients with APE were 0.801 and 0.675, respectively. The relapsed group showed significantly lower serum P62 expression (P<0.05) and significantly higher Beclin 1 expression than the non-relapsed group (P<0.05), and the AUCs of P62 and Beclin 1 in predicting the recurrence of APE were 0.815 and 0.769, respectively.